This Article Abstract Full Text (PDF) All Versions of this Article: 36/10/2281    most recent 01.STR.0000181088.76518.ecv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shearman, A. M. Articles by Miller, G. J. Search for Related Content PubMed PubMed Citation Articles by Shearman, A. M. Articles by Miller, G. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene SNP UniGene Substance via MeSH Medline Plus Health Information Stroke Related Collections Genetics of cardiovascular disease

(Stroke. 2005;36:2281.)
© 2005 American Heart Association, Inc.

Research Reports

Estrogen Receptor Gene Variation and the Risk of Stroke

Amanda M. Shearman, PhD; Jackie A. Cooper, MSc; Paul J. Kotwinski, MA, MRCP; Steve E. Humphries, PhD, FRCPath; Michael E. Mendelsohn, MD; David E. Housman, PhD George J. Miller, MD

From the Center for Cancer Research (A.M.S., D.E.H.), Massachusetts Institute of Technology, Cambridge, Mass; the Center for Cardiovascular Genetics (J.A.C., P.K., S.E.H.), Department of Medicine, Royal Free and University College London Medical School, Rayne Institute, University Street, London, UK; Tufts–New England Medical Center (M.E.M.), and Specialized Center of Research in Ischemic Heart Disease, Boston, Mass; and the Medical Research Council Cardiovascular Research Group (G.J.M.), Wolfson Institute of Preventive Medicine, Charterhouse Square, London, UK.

Correspondence to Amanda M. Shearman, PhD, 77 Massachusetts Ave, E17-536, Cambridge, MA 02139. E-mail shearman{at}mit.edu

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Appendix References

 
Background— Estrogen receptor (ESR1) gene variation is associated with a range of important estrogen-dependent characteristics, including responses of lipid profile and atherosclerotic severity to hormone replacement therapy, coronary heart disease risk, and migraine. The roles that reproductive steroids play in cerebrovascular pathophysiology and ischemia are an important area of investigation. Given that there is a significantly higher risk of myocardial infarction among men with the CC genotype (PP of PvuII) of c.454-397T>C (rs2234693), we asked whether this genotype is associated with a higher risk of stroke.

Methods— Relative risk of stroke by genotype was determined in 2709 participants of the Second Northwick Park Heart Study, white males with a mean baseline age 56 years and follow up 10.5 years.

Results— Compared with participants with the ESR1 c.454-397CT or TT genotype, those with the CC genotype had a relative risk of stroke of 1.92 (95% confidence interval, 1.06 to 3.48, P=0.03) after adjustment for age, primary care practice; additional adjustment for body mass index, serum cholesterol and triglyceride levels, hypertension, diabetes, and smoking status. Exclusion of stroke cases with coronary heart disease gave results that were essentially unchanged.

Conclusions— In this study, subjects with the common ESR1 c.454-397CC genotype have a substantial increase in risk of stroke. In another publication, other ESR1 variation was associated with migraine. We thus hypothesize that estrogen receptor variation may provide a basis for the established relationship among estrogens, migraine, and stroke.

Key Words: genetics • risk factors • stroke

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Appendix References

 
There is recent evidence for a role of estrogen receptor (ESR1) gene variation in determining a range of important estrogen-dependent characteristics, including responses of lipid profile and atherosclerotic severity to hormone replacement therapy, coronary reactivity, and coronary heart disease (CHD) risk.^1–6 The roles that reproductive steroids play in cerebrovascular pathophysiology and ischemia are an important area of ongoing investigation. Given that there is a significantly higher risk of myocardial infarction among men with the CC genotype (PP of PvuII)^4,5 of c.454-397T>C (rs2234693), we tested the hypothesis that the CC genotype is associated with a higher risk of stroke.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Appendix References

 
We studied white men from the prospective population-based Second Northwick Park Heart Study in the United Kingdom.⁷ Follow up is ongoing with a current median duration of 10.5 years. Strokes were categorized according to the International Classification of Diseases, Ninth Edition (ICD-9): cerebral artery occlusion (434.9, n=31), unspecific cerebrovascular accident (436.0, n=18), intracerebral hemorrhage (431.0, n=6), subarachnoid hemorrhage (430.0, n=0), and cerebral embolism (434.1, n=0) on the basis of clinical presentation, computed tomography (CT), lumbar puncture, or autopsy findings. Genotype data from 2709 men were included in the current study. (Please see additional information in the online only Appendix to this article available at http://www.strokeaha.org.)

	Results

Top Abstract Introduction Materials and Methods Results Discussion Appendix References

 
Individuals with stroke had higher baseline means or frequencies of the nonlipid-established cardiovascular disease risk factors (Table). In a model with adjustment for age and primary care practice, compared with men with the ESR1 c.454-397CT or TT genotype, those with the CC genotype had a relative risk of 1.92 (95% confidence interval [CI], 1.06 to 3.48, P=0.03). This result was essentially unchanged, at 1.84 (95% CI, 1.01 to 3.35, P=0.045), after additional adjustment for body mass index, serum cholesterol and triglyceride levels, hypertension, diabetes, and smoking status. Further adjustment of the model for CHD, or exclusion of participants with CHD, gave similar results. Survival curves were calculated for stroke by genotype (Figure).

View this table: [in this window] [in a new window]   Participant Characteristics

View larger version (8K): [in this window] [in a new window]   Survival curves for stroke by ESR1 c.454-397T>C genotype groups CC (dashed line) versus CT or TT (solid line) calculated with the Kaplan–Meier method.

Apart from diabetes, baseline characteristics (Table), high-density lipoprotein cholesterol, and Apo-A1 levels gave no evidence of association with genotype.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Appendix References

 
Estrogen receptors are required for normal vascular physiology in males,⁸ and in animal models, estrogen receptor plays a role in estradiol-mediated cerebral injury protection.⁹ The mechanisms that underlie the association seen here with stroke are not clear, although there is evidence from 2 groups that the ESR1 c.454-397C allele results in a relatively high level of ESR1 transcription.^6,10 Other polymorphisms in linkage disequilibrium with ESR1 c.454-397T>C may nevertheless be responsible for some or all of the observed association.^11,12 Our coincidental support for an association of genotype with diabetes is consistent with a report of impaired glucose tolerance and hyperinsulinemia in a man with a premature stop codon in both copies of ESR1.¹³ However, this result may be because of multiple testing, and a much larger study found no such evidence of association with diabetes.⁶

Importantly, the association of genotype with risk of stroke was independent of established cardiovascular risk factors, including diabetes, and was essentially unchanged after exclusion of stroke cases with CHD.

These results require replication in other studies of stroke among both ethnically similar and disparate subjects. We do not currently have access to such data, but our findings are strengthened by the fact that they resemble previous results for myocardial infarction in a Finnish Study and the Framingham Heart Study.^4,5 A common mechanism based on ESR1 variation may determine risk of both CHD and stroke. A recent report of association between another ESR1 polymorphism and migraine susceptibility¹⁴ makes variation in this gene a potential basis for the close but complex relationship among estrogens, migraine, and stroke.¹⁵ In men, the common ESR1 c.454-397CC genotype, present in approximately 20% of individuals, may be a risk factor for stroke and, if confirmed in replicate studies, may be useful for identifying at-risk subjects.

	Appendix

Top Abstract Introduction Materials and Methods Results Discussion Appendix References

 
Materials and Methods
Participants were registered with 9 primary care general practices in the United Kingdom. To be eligible for initial inclusion subjects had to be free from a history of unstable angina, myocardial infarction or evidence of silent infarction, coronary surgery, aspirin or anticoagulant therapy, cerebrovascular disease, malignancy (except skin cancer other than melanoma), or any condition precluding informed consent. Participants answered a health and life-style questionnaire at enrolment. Weight, height and systolic blood pressure were recorded and venous blood samples were collected for plasma and DNA analysis. Diabetes status was self-reported. Cholesterol and triglyceride concentrations were measured using automated enzyme procedures. Serum apolipoprotein-A1 (Apo-A1) was determined by immunoprecipitation, and high-density lipoprotein (HDL) cholesterol after precipitation of apolipoprotein-B containing particles with polyethylene glycol. Blood pressure was recorded twice per examination, with a random zero sphygmomanometer, after subjects had been seated for at least 5 min, and the results averaged for statistical analysis. Hypertension was defined as a systolic blood pressure 140 mm Hg and/or a diastolic blood pressure [mtqu]90 mm Hg, or the use of antihypertensive medication.

Strokes were defined as a rapid onset of focal or global loss of cerebral function lasting >24 hours or causing death beforehand, with no apparent cause other than cerebral ischemia or haemorrhage. Diagnosis was supported by CT in 30 of 31 coded 434.9, 5 of 18 coded 436.0, and 4 of 6 coded 431.0. Genotyping was carried out, with inclusion of positive and negative genotypic control samples on each plate, using automated Amplifluor-based methods. All subjects gave informed consent, and the examination protocols were approved by the appropriate Institutional Review Boards.

Statistical analysis was conducted using Intercooled STATA version 8.2. The association of genotype with risk of stroke was assessed using Cox proportional hazards model, with significance assessed by the likelihood ratio test. The threshold for statistical significance was set at P=0.05.

The study is powered to detect a relative risk of 2.25 (for CC versus CT or TT genotypes) with 80% power at the 5% level of significance.

Results
Genotype and allele frequencies were similar to those previously observed, with no significant deviation from Hardy-Weinberg expectations.

A covariate adjusted genotype model gave hazard ratios of 1.00 for TT, 1.10 (95% CI, 0.55-2.21) for TC, and 2.04 (95% CI, 0.96-4.34) for CC genotypes, P=0.12. From an additive model the hazard ratio for each C-allele was 1.46 (95% CI, 0.98-2.17) P=0.06. After additional adjustment for CHD the result was 1.0 for TT, 1.09 (0.54-2.21) for TC and 1.83 (0.86-3.91) for CC, P=0.22. For each C-allele the hazard ratio was 1.40 (0.94-2.08), P=0.10.

At baseline 8.9% (70) of TTs, 8.0% (109) of CTs and 8.8% (48) of CCs were on cholesterol lowering treatments (p=0.72). Of those with stroke 23.1% (3) of TTs, 16.0% (4) of CTs and 17.7% (3) of CCs were on cholesterol lowering treatment (p=0.90).

Of the 55 stroke patients 12 had CHD: 5 with TT, 4 with CT, and 3 with CC genotype. Additional adjustment of the model for CHD gave a relative risk for the CC genotype of 1.73 (95% CI, 0.95-3.15, P=0.07), while exclusion of participants with CHD gave a relative risk of 1.97 (95% CI, 1.01-3.84, P=0.048).

Analysis of baseline characteristics by genotype provided evidence for an association with diabetes, present in 1.9% (15) of TT, 3.0% (41) of TC, and 1.3% (7) of CC individuals. Logistic regression models of diabetes adjusted for age and primary care practice, and additionally for alcohol consumption, BMI, smoking status, hypertension, and high serum triglyceride levels provided similar, significant results for the genotype model (ORs for diabetes by genotype: TT 1.00, TC 1.58 [0.87-2.88], CC 0.66 [0.27-1.63], P=0.04; and TT 1.00, TC 1.66 [0.91-3.05], CC 0.62 [0.25-1.56], P=0.02 respectively). Among subjects with diabetes there was deviation from Hardy-Weinberg expectations (P=0.01).

Discussion
As we only studied Caucasian men from the United Kingdom and included adjustment for primary care practice at which the men were recruited it is unlikely that the results will have been affected by stratification. Limitations of our study are the small number and mixed etiologies of strokes. The study did not provide power to test separately for associations with type of stroke. Thus our study may underestimate the true size of effect that might be seen in a homogenous group of stroke cases. However, the fact that we are reporting a prospective study reduces the likelihood of bias that is inherent in case-control studies.

	Acknowledgments

 
We are indebted to all those who participated in the Study. This work was supported by a Specialized Center of Research in Ischemic Heart Disease from the National Institutes of Health’s National Heart, Lung and Blood Institute (NHLBI, P50 HL63494). The Second Northwick Park Heart Study was supported by the UK Medical Research Council, the British Heart Foundation (RG 2000/015), NHLBI 33014, RO1-HL65230, and Du Pont Pharma, Wilmington, De.

Received May 11, 2005; accepted May 12, 2005.

	References

Top Abstract Introduction Materials and Methods Results Discussion Appendix References

 

1. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002; 346: 967–974.[Abstract/Free Full Text]
2. Koivu TA, Fan YM, Mattila KM, Dastidar P, Jokela H, Nikkari ST, Kunnas T, Punnonen R, Lehtimaki T. The effect of hormone replacement therapy on atherosclerotic severity in relation to ESR1 genotype in postmenopausal women. Maturitas. 2003; 44: 29–38.[CrossRef][Medline] [Order article via Infotrieve]
3. Lehtimaki T, Laaksonen R, Mattila KM, Janatuinen T, Vesalainen R, Nuutila P, Laakso J, Jaakkola O, Koivula T, Knuuti J. Oestrogen receptor gene variation is a determinant of coronary reactivity in healthy young men. Eur J Clin Invest. 2002; 32: 400–404.[CrossRef][Medline] [Order article via Infotrieve]
4. Lehtimaki T, Kunnas TA, Mattila KM, Perola M, Penttila A, Koivula T, Karhunen PJ. Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. J Mol Med. 2002; 80: 176–180.[CrossRef][Medline] [Order article via Infotrieve]
5. Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn ME, Housman DE, Levy D. Association between Estrogen Receptor alpha gene variation and cardiovascular disease. J Am Med Assoc. 2003; 290: 2263–2270.[Abstract/Free Full Text]
6. Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A, Pols HA, Uitterlinden AG. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. J Am Med Assoc. 2004; 291: 2969–2677.[Abstract/Free Full Text]
7. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation. 2000; 102: 2816–2822.[Abstract/Free Full Text]
8. Mendelsohn ME, Rosano GM. Hormonal regulation of normal vascular tone in males. Circ Res. 2003; 93: 1142–1145.[Free Full Text]
9. Dubal DB, Zhu H, Yu J, Rau SW, Shughrue PJ, Merchenthaler I, et al. Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci U S A. 2001; 98: 1952–1957.[Abstract/Free Full Text]
10. Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002; 105: 1879–1882.[Abstract/Free Full Text]
11. Kunnas TA, Laippala P, Penttila A, Lehtimaki T, Karhunen PJ. Association of polymorphism of human alpha oestrogen receptor gene with coronary artery disease in men: a necropsy study. BMJ. 2000; 321: 273–274.[Free Full Text]
12. Kunnas TA, Lehtimaki T, Karhunen PJ, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, Knuuti J, Nikkari ST. Estrogen receptor genotype modulates myocardial perfusion in young men. J Mol Med. 2004; 82: 821–825.[CrossRef][Medline] [Order article via Infotrieve]
13. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994; 331: 1056–1061.[Abstract/Free Full Text]
14. Colson NJ, Lea RA, Quinlan S, MacMillan J, Griffiths LR. The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. Neurogenetics. 2004; 5: 129–133.[CrossRef][Medline] [Order article via Infotrieve]
15. Bousser MG. Estrogens, migraine, and stroke. Stroke. 2004; 35: 2652–2656.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				C. S. Weickert, A. L. Miranda-Angulo, J. Wong, W. R. Perlman, S. E. Ward, V. Radhakrishna, R. E. Straub, D. R. Weinberger, and J. E. Kleinman Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia Hum. Mol. Genet., August 1, 2008; 17(15): 2293 - 2309. [Abstract] [Full Text] [PDF]

				M. J. Bos, S. C.E. Schuit, P. J. Koudstaal, A. Hofman, A. G. Uitterlinden, and M. M.B. Breteler Variation in the Estrogen Receptor {alpha} Gene and Risk of Stroke: The Rotterdam Study Stroke, April 1, 2008; 39(4): 1324 - 1326. [Abstract] [Full Text] [PDF]

				K. M. Rexrode, P. M. Ridker, H. H. Hegener, J. E. Buring, J. E. Manson, and R. Y.L. Zee Polymorphisms and Haplotypes of the Estrogen Receptor-{beta} Gene (ESR2) and Cardiovascular Disease in Men and Women Clin. Chem., October 1, 2007; 53(10): 1749 - 1756. [Abstract] [Full Text] [PDF]

				M Alevizaki, K Saltiki, A Cimponeriu, I Kanakakis, N Xita, C C Alevizaki, I Georgiou, and H-L Sarika Severity of cardiovascular disease in postmenopausal women: associations with common estrogen receptor {alpha} polymorphic variants Eur. J. Endocrinol., April 1, 2007; 156(4): 489 - 496. [Abstract] [Full Text] [PDF]

				A. L. Quinn, J. M. Regan, J. M. Tobin, B. J. Marinik, J. M. McMahon, D. A. McNett, C. M. Sushynski, S. D. Crofoot, P. A. Jean, and K. P. Plotzke In Vitro and In Vivo Evaluation of the Estrogenic, Androgenic, and Progestagenic Potential of Two Cyclic Siloxanes Toxicol. Sci., March 1, 2007; 96(1): 145 - 153. [Abstract] [Full Text] [PDF]

				A. D. Kjaergaard, C. Ellervik, A. Tybjaerg-Hansen, C. K. Axelsson, M.-L. M. Gronholdt, P. Grande, G. B. Jensen, and B. G. Nordestgaard Estrogen Receptor {alpha} Polymorphism and Risk of Cardiovascular Disease, Cancer, and Hip Fracture: Cross-Sectional, Cohort, and Case-Control Studies and a Meta-Analysis Circulation, February 20, 2007; 115(7): 861 - 871. [Abstract] [Full Text] [PDF]

				C. J. Pepine, W. W. Nichols, and D. F. Pauly Estrogen and Different Aspects of Vascular Disease in Women and Men Circ. Res., September 1, 2006; 99(5): 459 - 461. [Full Text] [PDF]

				A. M. Shearman Oestrogen receptor genetics: a needle that cuts through many haystacks? Eur. Heart J., July 1, 2006; 27(13): 1519 - 1520. [Full Text] [PDF]

				S. P. Duckles, D. N. Krause, C. Stirone, and V. Procaccio Estrogen and mitochondria: a new paradigm for vascular protection? Mol. Interv., February 1, 2006; 6(1): 26 - 35. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 36/10/2281    most recent 01.STR.0000181088.76518.ecv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shearman, A. M. Articles by Miller, G. J. Search for Related Content PubMed PubMed Citation Articles by Shearman, A. M. Articles by Miller, G. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene SNP UniGene Substance via MeSH Medline Plus Health Information Stroke Related Collections Genetics of cardiovascular disease